---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-164459"
form_type: "8-K"
ticker: "ANTX"
cik: "0001880438"
company_name: "AN2 Therapeutics, Inc."
filed_at: "2023-06-09T23:59:59+00:00"
generated_at: "2026-06-14T04:20:39.511874+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.15
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# AN2 Therapeutics stockholders elect three Class I directors and ratify PwC as auditor

## Summary
- Elected Kabeer Aziz (14.78M for), Gilbert Lynn Marks (14.78M for), and Rob Readnour (14.61M for) as Class I directors.
- Ratified PricewaterhouseCoopers LLP as independent auditor for fiscal 2023: 16.56M for, 51.6K against.
- Quorum of 16,610,548 shares (85.5% of outstanding) present at June 7, 2023 annual meeting.
- Results based on proxy statement filed April 26, 2023; no other proposals voted.

## SEC filing metadata
- accession: 0001193125-23-164459
- form_type: 8-K
- ticker: ANTX
- cik: 0001880438
- company_name: AN2 Therapeutics, Inc.
- filed_at: 2023-06-09T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.15
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1880438/000119312523164459/0001193125-23-164459-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1880438/000119312523164459/d500763d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-164459
- JSON: https://secwatch.observer/filing/0001193125-23-164459.json
- Plain text: https://secwatch.observer/filing/0001193125-23-164459.txt

## Key facts
- Shareholder Votes
  AN2 Therapeutics, Inc. shareholders approved Election of three Class I directors: Kabeer Aziz, Gilbert Lynn Marks, M.D., and Rob Readnour, Ph.D. at the 2023-06-07 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2023-06-07
  source text: 1. To elect the nominees Kabeer Aziz, Gilbert Lynn Marks, M.D. and Rob Readnour, Ph.D. as Class I directors until the Company’s 2026 annual meeting of stockholders or until their respective successors have been elected or appointed. The voting results were as follows: Name Votes For Votes Withheld Broker Non-Votes Total Kabeer Aziz 14,783,208 747,428 1,079,912 16,610,548 Gilbert Lynn Marks, M.D. 14,781,503 749,133 1,079,912 16,610,548 Rob Readnour, Ph.D. 14,607,802 922,834 1,079,912 16,610,548
  evidence_url: https://www.sec.gov/Archives/edgar/data/1880438/000119312523164459/0001193125-23-164459-index.htm
- Shareholder Votes
  AN2 Therapeutics, Inc. shareholders approved Ratification of appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for fiscal year ending December 31, 2023. at the 2023-06-07 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2023-06-07
  source text: 2. To ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. The voting results were as follows: Votes For Votes Against Abstentions Total 16,558,919 51,629 0 16,610,548
  evidence_url: https://www.sec.gov/Archives/edgar/data/1880438/000119312523164459/0001193125-23-164459-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.